

NIPT SCREENING FOR TWIN ZYGOSITY AND GENETIC RISK FACTORS



The **Natera® Panorama®** non-invasive prenatal test (NIPT) now screens twin pregnancies for zygosity and chromosomal abnormalities. **Natera** says that **Panorama** is the first NIPT that can determine whether twins are monozygotic (identical) or dizygotic (non-identical/fraternal) as early as 9 weeks' gestation.

Building on its history as the only NIPT that can differentiate between the mother's and the baby's DNA, **Panorama** is now also the only NIPT to distinguish between each twin's DNA, says **Natera**. **Panorama's** unique technology enables it to determine zygosity and each twin's gender while also allowing it to identify risk for more genetic conditions in twin pregnancies than other NIPTs, including monosomy X, sex chromosome trisomies, and 22q11.2 deletion syndrome.

FOR MORE INFORMATION, VISIT:

<http://www.panoramatest.com/panorama-test/>

NEW DRUG FOR TREATING BACTERIAL VAGINOSIS



Solosec™ (secnidazole), a 5-nitroimidazole antibiotic, has been given FDA approval for treatment of bacterial vaginosis (BV) in adult women, according to manufacturer **Symbiomix Therapeutics**. The drug, consisting of oral granules, can be given as a single 2-g dose, and taken with or without a meal. **Symbiomix Therapeutics** says that **Solosec** is clinically proven to normalize BV symptoms of odor and discharge.

Symbiomix Therapeutics reported that FDA approval was supported by comprehensive studies that found the single-dose secnidazole 2g was efficacious. All treatment-emergent adverse effects were mild or moderate in intensity; no serious adverse events were reported. **Solosec** will be available to patients in the first quarter of 2018.

FOR MORE INFORMATION, VISIT:

<https://symbiomix.com/sym-1219/>